Young A, et al. - A sum of 93 individuals (mean age 54.9 years) was examined to study the prevalence, symptoms, treatment, and consequences for with pulmonary hypertension (PH) cases in systemic sclerosis (SSc)-linked interstitial lung disease (ILD) (SSc-ILD) cohort. About 82.8% of candidates were treated with ILD therapy whereas 82.8% with PAH therapy. They noted 97%, survival rate at 3 years after SSc-ILD diagnosis for all the cases. Ninety-one percent survival rate was recorded for those with SSc-ILD and PH at 3 years after PH diagnosis. Hence, they suggested evaluation of coexisting PH among subjects with SSc-ILD.